JPWO2022109307A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022109307A5 JPWO2022109307A5 JP2023530278A JP2023530278A JPWO2022109307A5 JP WO2022109307 A5 JPWO2022109307 A5 JP WO2022109307A5 JP 2023530278 A JP2023530278 A JP 2023530278A JP 2023530278 A JP2023530278 A JP 2023530278A JP WO2022109307 A5 JPWO2022109307 A5 JP WO2022109307A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- pharmaceutical composition
- use according
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115969P | 2020-11-19 | 2020-11-19 | |
| US63/115,969 | 2020-11-19 | ||
| US202163154652P | 2021-02-26 | 2021-02-26 | |
| US63/154,652 | 2021-02-26 | ||
| US202163158849P | 2021-03-09 | 2021-03-09 | |
| US63/158,849 | 2021-03-09 | ||
| US202163173361P | 2021-04-10 | 2021-04-10 | |
| US63/173,361 | 2021-04-10 | ||
| PCT/US2021/060151 WO2022109307A1 (en) | 2020-11-19 | 2021-11-19 | Treatment of kras mutant cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500288A JP2024500288A (ja) | 2024-01-09 |
| JPWO2022109307A5 true JPWO2022109307A5 (https=) | 2024-11-27 |
| JP2024500288A5 JP2024500288A5 (https=) | 2024-11-27 |
Family
ID=81709695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530278A Pending JP2024500288A (ja) | 2020-11-19 | 2021-11-19 | Ｋｒａｓ変異癌の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240016781A1 (https=) |
| EP (1) | EP4247806A4 (https=) |
| JP (1) | JP2024500288A (https=) |
| KR (1) | KR20230148144A (https=) |
| AU (1) | AU2021381423A1 (https=) |
| CA (1) | CA3198938A1 (https=) |
| IL (1) | IL302925A (https=) |
| MX (1) | MX2023005806A (https=) |
| WO (1) | WO2022109307A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| EP4376839A4 (en) * | 2021-07-26 | 2025-10-15 | Vincerx Pharma Inc | SELECTIVE CDK9 INHIBITOR FOR THE TREATMENT OF RAS MUTANT CANCER |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| IL319991A (en) * | 2022-10-03 | 2025-06-01 | Prelude Therapeutics Inc | Cancer treatment using combinations of SMARCA2 inhibitors and KRAS-targeted therapies |
| WO2024173833A1 (en) * | 2023-02-16 | 2024-08-22 | Mei Pharma, Inc. | Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563596B2 (en) * | 2006-06-21 | 2013-10-22 | Piramal Enterprises Limited | Enantiomerically pure compounds for the treatment of proliferative disorders |
| CN104220066A (zh) * | 2010-11-19 | 2014-12-17 | 皮拉马尔企业有限公司 | 紫杉醇和cdk抑制剂药物组合物 |
| CN105530931B (zh) * | 2013-07-12 | 2019-11-08 | 皮拉马尔企业有限公司 | 用于治疗黑素瘤的药物组合 |
| RU2726367C2 (ru) * | 2016-03-28 | 2020-07-13 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
| US20220175750A1 (en) * | 2018-04-23 | 2022-06-09 | The Regents Of The University Of California | Sustained release formulation for local delivery of cdk9 inhibitors |
| WO2020046966A1 (en) * | 2018-08-27 | 2020-03-05 | Kura Oncology, Inc. | Treatment of adenocarcinomas with mapk pathway inhibitors |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| AU2020271908B2 (en) * | 2019-04-11 | 2025-12-04 | Mei Pharma, Inc. | Voruciclib poly morphs and methods of making and using thereof |
| CA3148504A1 (en) * | 2019-08-08 | 2021-02-11 | Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center | Combination therapy for treatment of cancer |
| WO2022217133A1 (en) * | 2021-04-10 | 2022-10-13 | Mei Pharma, Inc. | Voruciclib dosing regimens and methods of treatment including the same |
-
2021
- 2021-11-19 WO PCT/US2021/060151 patent/WO2022109307A1/en not_active Ceased
- 2021-11-19 EP EP21895697.7A patent/EP4247806A4/en active Pending
- 2021-11-19 US US18/253,481 patent/US20240016781A1/en active Pending
- 2021-11-19 IL IL302925A patent/IL302925A/en unknown
- 2021-11-19 CA CA3198938A patent/CA3198938A1/en active Pending
- 2021-11-19 JP JP2023530278A patent/JP2024500288A/ja active Pending
- 2021-11-19 MX MX2023005806A patent/MX2023005806A/es unknown
- 2021-11-19 KR KR1020237020122A patent/KR20230148144A/ko active Pending
- 2021-11-19 AU AU2021381423A patent/AU2021381423A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240299388A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| Lissoni et al. | A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms | |
| JPWO2023140329A5 (https=) | ||
| JP2019532051A5 (https=) | ||
| JP5745678B2 (ja) | Ｐｉ３ｋ阻害剤とｍｅｋ阻害剤の併用 | |
| EA037152B1 (ru) | Способ лечения рака | |
| JP7504097B2 (ja) | Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法 | |
| JPWO2022271964A5 (https=) | ||
| JP2021524835A5 (https=) | ||
| JPWO2022109307A5 (https=) | ||
| JP2019501185A (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| EP2036903B1 (en) | Potentiator of radiation therapy | |
| KR102868121B1 (ko) | 메타 아비산염을 포함하는 약학 조성물 및 제조 방법 | |
| CN102770026B (zh) | 组合 | |
| Musumeci et al. | Analogs, formulations and derivatives of imatinib: a patent review | |
| JPWO2021222278A5 (https=) | ||
| Baetz et al. | A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours | |
| D’Angelo et al. | Prognostic value of nephromegaly at diagnosis of childhood acute lymphoblastic leukemia | |
| CN120282786A (zh) | 治疗晚期实体肿瘤的方法 | |
| Lam et al. | Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma | |
| Kuo et al. | Monthly tegafur–uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study | |
| Nomura et al. | Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma | |
| TW202304438A (zh) | 使用貝伐拉非尼及考比替尼或使用貝伐拉非尼、考比替尼及阿替利珠單抗的組合療法 | |
| Aoki et al. | Targeted therapy followed by cytotoxic chemotherapy in preoperative patients with locally advanced lung adenocarcinoma | |
| TWI709402B (zh) | 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物 |